Prognostic utility of the soluble CD40 ligand in acute coronary syndrome

Coronary Artery Disease

Volumn 25, Issue 7, 2014, Pages 548-549

  Lindberg, Søren ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; SOLUBLE CD40 LIGAND; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DISEASE ASSOCIATION; EDITORIAL; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; BLOOD; FEMALE; HEART INFARCTION; MALE;

ACUTE CORONARY SYNDROME; CD40 LIGAND; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION;

EID: 84926638910     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000155     Document Type: Editorial

References (19)

1. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001;89:1092-1103.
2. Leroyer AS, Rautou PE, Silvestre JS, Castier Y, Lesèche G, Devue C, et al. CD40 ligand + microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol 2008;52:1302-1311.
3. Pusuroglu H, Akgul O, Erturk M, Uyarel H, Bulut U, Akkaya E, et al. Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Coron Artery Dis 2014;25:558-564.
4. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002;12:27-32.
5. Tousoulis D, Antoniades C, Nikolopoulou A, Koniari K, Vasiliadou C, Marinou K, et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 2007;37:623-628.
6. Yan JC, Wu ZG, Kong XT, Zong RQ, Zhan LZ. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome. Acta Pharmacol Sin 2004;25:251-256.
7. Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 2004;93:6-9.
8. De Lemos JA, Zirlik A, Schönbeck U, Varo N, Murphy SA, Khera A, et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005;25:2192-2196.
9. Varo N, De Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003;108:1049-1052.
10. L'Allier PL, Tardif JC, Grégoire J, Joyal M, Lespérance J, Fortier A, Guertin MC. Sustained elevation of serum CD40 ligand levels one month after coronary angioplasty predicts angiographic restenosis. Can J Cardiol 2005;21:495-500.
11. Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, Morrow DA. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis 2008;26:79-84.
12. Tan J, Hua Q, Gao J, Fan ZX. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008;31:413-418.
13. Morrow DA, Sabatine MS, Brennan ML, De Lemos JA, Murphy SA, Ruff CT, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008;29:1096-1102.
14. Jefferis BJ, Whincup PH, Welsh P, Wannamethee SG, Rumley A, Lawlor DA, et al. Prospective study of circulating soluble CD40 ligand concentrations and the incidence of cardiovascular disease in a nested prospective case-control study of older men and women. J Thromb Haemost 2011;9:1452-1459.
15. Azar RR, Kassab R, Zoghbi A, Aboujaoudé S, El-Osta H, Ghorra P, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006;151:521. e1-521. e4.
16. Vavuranakis M, Latsios G, Aggelis D, Bosinakou I, Karambelas I, Tousoulis D, et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Ther 2006;28:860-871.
17. Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CP. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 2010;33:206-212.
18. Furman MI, Krueger LA, Linden MD, Fox ML, Ball SP, Barnard MR, et al. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 2005;3:312-320.
19. Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem 2010;43:666-670.